Innovational Combinational Therapies Utilizing Tumor-targeted Oncolytic And Adoptive T-cell Therapy For Lung Cancer And Mesothelioma | 25077
Journal of Cancer Science & Therapy
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Our laboratory has developed innovative tumor-targeted biological therapies ? a) oncolytic viral therapy, geneticallyengineered
replicative-competent attenuated viruses that can selectively infect, replicate, lyse cancer cells sparing normal
tissue, and b) Adoptive T-cell therapy, engineering patient?s own immune cells to target a specific antigen expressed on cancer
cells sparing normal tissues. Following extensive preclinical development, we now are conducting phase I clinical trials to
assess safety and maximum tolerable dose. To further the incorporation of these novel therapies, we have strong preclinical
data combining these therapies with current standard of care chemotherapy and radiation therapy. More importantly, our
innovative approach includes administering this biological therapeutics regionally into the pleural cavity by use of tunneled
pleural catheters. Our unpublished data shows that early therapeutic agent activation by regional administration facilitates
better local as well as systemic immune responses. These innovative combinational therapies will facilitate better tumor
eradication and long-term prognosis.
Prasad S Adusumilli has completed his M.B.B.S. at the age of 22 years from Guntur Medical College and postdoctoral studies from AIIMS, New Delhi, Southampton
University, UK and from Memorial Sloan Kettering Cancer Center (MSKCC) and University of Pittsburgh, USA. He is now the Deputy Chief of Thoracic Surgery
at the MSKCC and Member in Center for Cell Engineering at MSKCC. He has published more than 100 papers in reputed journals including JCO and JNCI. He
is invited to be the Deputy Chief Editor for Molecular Therapy Oncolytics Journal (Nature Group Publication) serves as an editorial board member of PLOSOne.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals